RCT: In patients with heart failure and preserved ejection fraction, Sacubitril/Valsartan reduced NT-proBNP, but did not improve exercise capacity and was associated with increased risk of hypotension (14.1% vs 5.5%).

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Quality of Life and Exercise Ability in Heart Failure With Preserved Ejection Fraction: No Time for Therapeutic Complacency – JAMA (free for a limited period)

Commentary on Twitter

Study found treatment w sacubitril/valsartan vs standard treatment w enalapril, valsartan, or placebo resulted in a statistically significant reduction in plasma NT-proBNP levels at 12 wk but no significant change in the 6-minute walking distance at 24 wk https://t.co/rwlOXWwcz2 pic.twitter.com/fRUPgQpU9J

— JAMA (@JAMA_current) November 16, 2021